Clinical Trial Update: Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls. [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating the effect of ofatumumab in treatment-naïve, very early relapsing-remitting multiple sclerosis patients. Results have been p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Kesimpta (ofatumumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapse Remitting Multiple Sclerosis | Phase 4 | Status: COMPLETED | Results posted: 2026-02-27